From biosimilar insulin to a full-scale protein production pipeline
rBIO is building a next-generation biosimilar pipeline powered by our high-yield microbial expression platform. We’re starting with insulin — and expanding to critical peptide-based therapies.
Our development pipeline
We’re advancing a focused pipeline of biosimilar drug candidates produced via our high-yield microbial expression platform. These therapies are selected for their high demand, vulnerable supply chains, and potential for cost-effective domestic manufacturing.
| Candidate | Target Molecule | Indication/Use | Stage | Notes |
|---|---|---|---|---|
| R-biolin | Human insulin | Diabetes | ✅ Preclinical complete, preparing for clinical trial | Bioequivalent to Novolin® R |
| Levemir® biosimilar | Insulin detemir | Long-acting insulin (basal) | 🧪 Early R&D | Addresses gap left by Levemir® withdrawal |
| rBIO-003 | Epinephrine | Anaphylaxis | 🔬 Discovery | Scalable EpiPen alternative |
| rBIO-004 | Erythropoietin (EPO) | Anemia, CKD | 🔬 Discovery | Lower-cost biosimilar |
R-biolin™: our lead candidate
R-biolin is a biosimilar insulin developed to match the performance and pharmacokinetics of Novolin® R — a widely used, short-acting human insulin.
✅ Preclinical validation complete
🐁 Demonstrated bioequivalence to Novolin® R in in vivo animal studies
🧬 Produced using rBIO’s proprietary expression platform (2x yield vs. legacy methods)
🏭 Scalable for clinical and commercial production in U.S. facilities
rBIO is now preparing R-biolin for clinical trials and seeking partners to support late-stage development and market entry.
Our strategy
rBIO’s platform is designed to address three critical challenges in today’s biologics landscape:
High-demand, high-cost therapies
We prioritize targets like insulin and erythropoietin where patient access and affordability are at risk.Vulnerable or discontinued drugs
As major players shift away from older biologics (e.g., Levemir®), rBIO is stepping in to fill the supply gap.Domestic manufacturing resilience
Our recombinant platform is built for U.S.-based production, reducing dependence on fragile global supply chains.
With every candidate we pursue, our goal is the same: to lower costs, restore availability, and modernize the biologics supply chain from the ground up.
Let’s build the future together
rBIO is currently engaging with:
Clinical research organizations (CROs)
Contract development and manufacturing organizations (CDMOs)
Strategic pharma partners
Public sector health stakeholders
If you are interested in partnering on clinical development, manufacturing, or distribution of any rBIO drug candidates, we want to hear from you.
Contact us
With a home base in Houston, Texas, rBIO sits at a US epicenter of innovation in healthcare and biotechnology.
We are currently engaging with strategic partners, CROs, CDMOs, and early-stage investors.